Duchenne muscular dystrophy: Current state and therapeutic perspectives

被引：0
|
作者：
Le Guen, Y. T. [1 ]
Le Gall, T. [1 ]
Laurent, V [1 ]
D'Arbonneau, F. [1 ]
Braun, S. [2 ]
Montier, T. [1 ,3 ]
机构：
[1] Univ Bretagne Occidentale, INSERM, Genet Genom Fonct & Biotechnol, EFS,UMR 1078, 22 Rue Camille Desmoulins,CS 93837, F-29238 Brest 3, France
[2] AFM Telethon, 1 Rue Int,BP59, F-91002 Evry, France
[3] CHRU Brest, Serv Genet Med & Biol Reprod, Ctr Reference Malad Rares Malad Neuromusculaires, F-29200 Brest, France
来源：
BULLETIN DE L ACADEMIE NATIONALE DE MEDECINE | 2021年 / 205卷 / 05期
关键词：
Muscular Dystrophy; Duchenne; Therapeutics; Gene Therapy; GENE-THERAPY; FEMALE CARRIERS; MUSCLE; GLUCOCORTICOIDS; CHILDREN; VECTORS; IMPACT;
D O I：
10.1016/j.banm.2020.10.019
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Duchenne muscular dystrophy is one of the most frequent muscular dystrophies, with 250,000 affected people worldwide. It results from mutations occurring in the dystrophin gene, the largest known in the human genome. Despite current therapies allow for a better clinical prognosis, the life span and the quality of life of patients still remain clearly lower than those in the general population. New therapeutic approaches are currently investigated, giving new perspectives and hopes for the care of this severe disease. (C) 2021 l'Academie nationale de medecine. Published by Elsevier Masson SAS. All rights reserved.
引用
收藏
页码：509 / 518
页数：10
相关论文
共 50 条
  • [21] A state-of-the-art review of tamoxifen as a potential therapeutic for duchenne muscular dystrophy
    Botti, Valeria
    Menzel, Olivier
    Staedler, Davide
    [J]. FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [22] Current and Emerging Therapies for Duchenne Muscular Dystrophy
    Megan Crone
    Jean K. Mah
    [J]. Current Treatment Options in Neurology, 2018, 20
  • [23] Current Concepts in the Management of Duchenne Muscular Dystrophy
    Rinaldi R.J.
    Mayer M.P.
    Dichiaro M.R.
    [J]. Current Physical Medicine and Rehabilitation Reports, 2013, 1 (2) : 65 - 71
  • [24] Current treatment of adult Duchenne muscular dystrophy
    Wagner, Kathryn R.
    Lechtzin, Noah
    Judge, Daniel P.
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE, 2007, 1772 (02): : 229 - 237
  • [25] Current Pharmacological Strategies for Duchenne Muscular Dystrophy
    Yao, Shanshan
    Chen, Zihao
    Yu, Yuanyuan
    Zhang, Ning
    Jiang, Hewen
    Zhang, Ge
    Zhang, Zongkang
    Zhang, Baoting
    [J]. FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2021, 9
  • [26] Pathophysiology of duchenne muscular dystrophy: Current hypotheses
    Deconinck, Nicolas
    Dan, Bernard
    [J]. PEDIATRIC NEUROLOGY, 2007, 36 (01) : 1 - 7
  • [27] Duchenne muscular dystrophy: current cell therapies
    Sienkiewicz, Dorota
    Kulak, Wojciech
    Okurowska-Zawada, Bozena
    Paszko-Patej, Grazyna
    Kawnik, Katarzyna
    [J]. THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2015, 8 (04) : 166 - 177
  • [28] CURRENT STATUS OF DUCHENNE MUSCULAR-DYSTROPHY
    IANNACCONE, ST
    [J]. PEDIATRIC CLINICS OF NORTH AMERICA, 1992, 39 (04) : 879 - 894
  • [29] Current care strategies for Duchenne muscular dystrophy
    Fujak, A.
    Haaker, G.
    Funk, J.
    [J]. ORTHOPADE, 2014, 43 (07): : 636 - 642
  • [30] Biomarkers of Duchenne muscular dystrophy: current findings
    Szigyarto, Cristina Al-Khalili
    Spitali, Pietro
    [J]. DEGENERATIVE NEUROLOGICAL AND NEUROMUSCULAR DISEASE, 2018, 8 : 1 - 13
12345